Bellicum Pharma (BLCM) Selected for Inclusion in NASDAQ Biotechnology Index

Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) today announced that the Company has been selected for inclusion in the NASDAQ Biotechnology Index® (Nasdaq: NBI). This addition will be effective prior to market open on Monday, December 21, 2015.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology and ranked on an annual basis. All securities in the NASDAQ Biotechnology Index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market, and meet minimum market value and share volume requirements among other criteria. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit www.nasdaq.com.

You May Also Be Interested In

• Brown-Forman CEO Lawson Whiting to retire after nearly 30 years
• Datavault AI names CBIZ CPAs as its new accounting firm
• PagerDuty names Arnaud Lagarde as VP of EMEA